Finding the fundamental pathway in ALD pathogenesis
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
List view / Grid view
Liver-specific knockdown of TRPC3 enhanced alcohol's inhibitory effect on AMPK through a mechanism of Ca2+-dependent CaMKK2 activation.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
A potential link between truncating variants and the development of DCM has been found, and a patient-focused registry about PPCM was made.
Oligodendrocyte precursor cells and the synapses they form with neurons could be relevant to many disease conditions, including cancer.
Using clinical E. coli bacteraemia isolates, researchers found that high-persister mutants evolved which contributed to antibiotic failure.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
Genetic factors that promote disease development accumulated in CD4+ T cells exhibiting specific gene programmes.
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.
Disruptions in TP53 and RB1 are key influencers that cause changes in the risk of mutations across chromosomes.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
Data from protein analyses, combined with data from patient journals, enabled the discovery of proteins that predict disease progression.
Researchers found that ANG in its mutated form slows stem cell differentiation, resulting in neurodevelopmental defects in adult nerve cells.
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.